Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) EBT Margin (2022 - 2025)

Arcutis Biotherapeutics has reported EBT Margin over the past 4 years, most recently at 14.23% for Q4 2025.

  • Quarterly results put EBT Margin at 14.23% for Q4 2025, up 2932.0% from a year ago — trailing twelve months through Dec 2025 was 4.05% (up 6761.0% YoY), and the annual figure for FY2025 was 4.02%, up 7967.0%.
  • EBT Margin for Q4 2025 was 14.23% at Arcutis Biotherapeutics, up from 7.55% in the prior quarter.
  • Over the last five years, EBT Margin for ARQT hit a ceiling of 14.23% in Q4 2025 and a floor of 14856.41% in Q3 2022.
  • Median EBT Margin over the past 4 years was 115.97% (2023), compared with a mean of 1610.72%.
  • Biggest five-year swings in EBT Margin: skyrocketed 1471727bps in 2023 and later soared 2932bps in 2025.
  • Arcutis Biotherapeutics' EBT Margin stood at 2432.25% in 2022, then soared by 80bps to 489.86% in 2023, then soared by 97bps to 15.09% in 2024, then skyrocketed by 194bps to 14.23% in 2025.
  • The last three reported values for EBT Margin were 14.23% (Q4 2025), 7.55% (Q3 2025), and 19.07% (Q2 2025) per Business Quant data.